Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of additional dose(s) of BNT162b2 in previously vaccinated healthy individuals
2021-005197-25Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Primary endpoint: Primary endpoints (Substudy A). Started Nov 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005197-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005197-25.